{kanada_flagge}The global workplace safety market was worth around $12.8 billion in 2021 and is forecast to increase in volume to $39 billion by 2031, growing at an annual rate of 12.2%. At the same time, the drug screening market is estimated to grow at a rate of 15.97% from 2022 to 2029, and then be worth nearly $22.24 billion. These are the markets in which Predictmedix Inc (CSE PMED / WKN A2P20P) is moving, a pioneer in the field of AI-assisted diagnostics. And now with the help of a U.S. patent for its AI-assisted technology for non-invasive detection of impairment from alcohol and cannabis use!
Conclusion: Receiving the U.S. patent for the AI-assisted screening technology is, in our view, a significant milestone for Predictmedix. As Dr. Rahul Kushwah, COO of the company, explained, the Predictmedix technology has the potential to revolutionize the way companies and organizations screen for impairments. According to Kushwah, Predictmedix also has numerous promising opportunities in the pipeline and is continuously working to innovate and improve its technology to remain at the spearhead of the AI revolution. With the receipt of this patent, the company’s position in the health screening market has been strengthened and it now looks forward to continuing to expand its product portfolio in the future, Kushwah said.
{kanada_flagge}The global workplace safety market was worth around $12.8 billion in 2021 and is forecast to increase in volume to $39 billion by 2031, growing at an annual rate of 12.2%. At the same time, the drug screening market is estimated to grow at a rate of 15.97% from 2022 to 2029, and then be worth nearly $22.24 billion. These are the markets in which Predictmedix Inc (CSE PMED / WKN A2P20P) is moving, a pioneer in the field of AI-assisted diagnostics. And now with the help of a U.S. patent for its AI-assisted technology for non-invasive detection of impairment from alcohol and cannabis use!
The patented technology uses multispectral imaging and speech analysis to identify and extract features of an individual, allowing the technology to infer whether the person is showing signs of impairment. The technology is part of Predictmedix’s fit-for-duty screening solutions, which allow non-contact and unbiased screening for impairment, extreme fatigue and infectious diseases.
NEW: Follow us on Twitter for more English content!
Add to that the walk-in Safe Entry system, which uses multispectral imaging and AI computing, to gather important physiological information in just a few – two to three – seconds to determine a person’s physiological state. An important advantage over urine and breath alcohol testing is that Safe Entry works without touching, so no biological fluids are taken. Safe Entry is supported by AI and ML algorithms that provide a fair and accurate assessment of the person’s physiological state.
Conclusion: Receiving the U.S. patent for the AI-assisted screening technology is, in our view, a significant milestone for Predictmedix. As Dr. Rahul Kushwah, COO of the company, explained, the Predictmedix technology has the potential to revolutionize the way companies and organizations screen for impairments. According to Kushwah, Predictmedix also has numerous promising opportunities in the pipeline and is continuously working to innovate and improve its technology to remain at the spearhead of the AI revolution. With the receipt of this patent, the company’s position in the health screening market has been strengthened and it now looks forward to continuing to expand its product portfolio in the future, Kushwah said.
Subscribe to the Goldinvest.de newsletter now
Follow Goldinvest.de on LinkedIn
Disclaimer: GOLDINVEST Consulting GmbH publishes comments, analyses and news on https://goldinvest.de. These contents serve exclusively the information of the readers and do not represent a call to action, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. Furthermore, they are in no way a substitute for individual expert investment advice and do not constitute an offer to sell the discussed stock(s) or a solicitation to buy or sell securities. It is expressly not a financial analysis, but a promotional/journalistic text. Readers who make investment decisions or execute transactions on the basis of the information provided here do so exclusively at their own risk. There is no contractual relationship between GOLDINVEST Consulting GmbH and its readers or the users of its offers, because our information refers only to the company, but not to the investment decision of the reader.
The acquisition of securities is associated with high risks, which can lead to a total loss of the invested capital. The information published by GOLDINVEST Consulting GmbH and its authors is based on careful research. Nevertheless, any liability for financial losses or the content guarantee for topicality, correctness, adequacy and completeness of the articles offered here is expressly excluded. Please also note our terms of use.
Pursuant to §34b WpHG and §48f Abs. 5 BörseG (Austria) we point out that GOLDINVEST Consulting GmbH and/or partners, principals or employees of GOLDINVEST Consulting GmbH hold shares in Predictmedix and therefore a conflict of interest exists. GOLDINVEST Consulting GmbH also reserves the right to buy or sell shares of the company at any time. Furthermore, GOLDINVEST Consulting GmbH is remunerated by Predictmedix for reporting on the company. This is another clear conflict of interest.
